검색
Valneva SE
VALN관심 목록에 추가
4.970USD
-0.120-2.36%
종가 07-31 16:00（ET）시세는 15분 지연됩니다
469.87M시가총액
손실P/E TTM
자세한 내용은 Valneva SE 회사
Valneva SE is a France-based company that specializes in the development, manufacture and commercialization of vaccines to protect people from infectious diseases through preventative medicine. The Company's portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT, for the prevention of Japanese Encephalitis, and DUKORAL, which is indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by Enterotoxigenic escherichia coli (ETEC). The Company has also vaccines in development, including candidates against Lyme disease, COVID-19 and chikungunya. Its technologies and services segment cooperates with various pharmaceutical companies using its platform: EB66 vaccine production cell line and IC31 adjuvant. The Company is focused on research and development (R&D) programs, as well as holds investment in product candidates and commercial products.
Valneva SE 정보
종목 코드 VALN
회사 이름Valneva SE
상장일Jun 28, 2007
CEOLingelbach (Thomas)
직원 수- -
유형Depository Receipt
회계 연도 종료Jun 28
주소6, Rue Alain Bombard
도시SAINT-HERBLAIN
증권 거래소NASDAQ OMX - NASDAQ BASIC
국가France
우편 번호44800
전화33228073710
웹사이트https://valneva.com/
종목 코드 VALN
상장일Jun 28, 2007
CEOLingelbach (Thomas)
Valneva SE의 회사 임원진
이름
이름/직위
직위
주식 보유
변동
Mr. Franck Grimaud
Mr. Franck Grimaud
Chief Business Officer
Chief Business Officer
--
--
Mr. James R. Sulat
Mr. James R. Sulat
Independent Vice Chairman of the Board
Independent Vice Chairman of the Board
--
--
Mr. Thomas Lingelbach
Mr. Thomas Lingelbach
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Anne-Marie Graffin
Ms. Anne-Marie Graffin
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Juan Carlos Jaramillo
Dr. Juan Carlos Jaramillo
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Vincent Dequenne
Mr. Vincent Dequenne
Chief Operating Officer
Chief Operating Officer
--
--
Mr. Peter Buehler
Mr. Peter Buehler
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Dipal Patel
Ms. Dipal Patel
Chief Commercial Officer
Chief Commercial Officer
--
--
Mr. James Connolly
Mr. James Connolly
Independent Director
Independent Director
--
--
Ms. Mailys Ferrere
Ms. Mailys Ferrere
Director, Representative of Bpifrance Participations SA
Director, Representative of Bpifrance Participations SA
--
--
더 보기
이름
이름/직위
직위
주식 보유
변동
Mr. Franck Grimaud
Mr. Franck Grimaud
Chief Business Officer
Chief Business Officer
--
--
Mr. James R. Sulat
Mr. James R. Sulat
Independent Vice Chairman of the Board
Independent Vice Chairman of the Board
--
--
Mr. Thomas Lingelbach
Mr. Thomas Lingelbach
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Anne-Marie Graffin
Ms. Anne-Marie Graffin
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Juan Carlos Jaramillo
Dr. Juan Carlos Jaramillo
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Vincent Dequenne
Mr. Vincent Dequenne
Chief Operating Officer
Chief Operating Officer
--
--
자주 묻는 질문
Valneva SE의 상위 5대 주주는 누구인가요?
Valneva SE의 상위 5대 주주는 다음과 같습니다: Mr. Franck Grimaud
Valneva SE(VALN)의 주식을 보유한 기관은 몇 개입니까?
2026Q1 기준으로, Valneva SE의 주식을 보유한 기관은 총 36곳이며, 이들이 보유한 주식의 총 가치는 약 5.21M로 전체 발행 주식의 5.50%를 차지합니다. 이는 2025Q4 대비 -309162.00 증가한 수치입니다.
Valneva SE의 최대 수익원은 무엇인가요?
2026Q1 기준, Valneva SE의 IXIARO 부문이 가장 높은 매출을 기록했으며, 금액은 98.42M로 전체 매출의 56.35%를 차지했습니다.